Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias.
We studied the diagnostic role of CFC assays in myelodysplastic syndromes (MDS) using CFC data from bone marrow (BM) and peripheral blood (PB) of 221 MDS patients, 51 patients with non-malignant causes of cytopenia and/or dysplasia and 50 normal controls. A consistent decrease in BM but not PB multi-lineage and erythroid progenitor frequencies was seen in patients with MDS compared to controls (P<0.05). Automated distinction showed a sensitivity of 87+/-6% and a specificity of 71+/-11% in classifying MDS patients. In conclusion, a defect in early hematopoietic progenitor activity, in particular erythroid activity, distinguishes MDS from non-MDS.
Vercauteren
Suzanne M
SM
Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, Canada.
Bashashati
Ali
A
Wu
Donghong
D
Brinkman
Ryan R
RR
Eaves
Connie
C
Eaves
Allen
A
Karsan
Aly
A
D019070:Cell Lineage; D016000:Cluster Analysis; D003937:Diagnosis, Differential; D006402:Hematologic Diseases / Q000175:diagnosis*; D006801:Humans; D007621:Karyotyping; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D012680:Sensitivity and Specificity